COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, New York Hospital Queens, Cardiovascular Research Foundation, Columbia University, Universidad de Alcalá, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, University of Insubria, The University of Texas Health Science Center at Houston, Chinese PLA General Hospital, Union Hospital, Huazhong University of Science and Technology, Hospital of the University of Pennsylvania, Philadelphia VA Medical Center, University of Pennsylvania, University of Vermont Medical Center, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Sotiria General Hospital, Beth Israel Deaconess Medical Center, Harvard University, University of Verona, Westmead Hospital, Loyola University Medical Center, University of Chicago, NorthShore University HealthSystem, University of Liverpool, Society for Vascular Surgery, Liverpool Heart and Chest Hospital, Aalborg University, Icahn School of Medicine at Mount Sinai, University of Milan, Ospedale Papa Giovanni XXIII, Auckland City Hospital, St Thomas' Hospital, Hofstra University, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, McMaster University, University of Michigan, Michigan Medicine, University of Cologne, Population Health Research Institute, University Hospital Cologne, Hamilton Health Sciences, Massachusetts General Hospital, Sechenov University, Thrombosis and Atherosclerosis Research Institute, Ottawa Hospital, Yale University, Ottawa Hospital Research Institute, Brigham and Women's Hospital, Vanderbilt University, Inserm, Université Paris Cité, Royal Brompton Hospital, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Imperial College London, Cardiovascular Institute of the South, Mount Sinai Hospital, Universidad Católica de Murcia, Yale New Haven Health System, Johannes Gutenberg University Mainz